Loading
If this is the first time anyone has visited this substance, we may be fetching live data from TGA Product Information, PBS, and state framework sources — that can take up to a minute. Cached substances load in a second or two.
Curated subset. The full adverse-effect list is in the TGA Product Information; click any citation above to open it.
“Arsenic trioxide can induce partial differentiation and apoptosis of leukaemic cells in vitro. There is also evidence that its other known pharmacological effects (degradation of specific APL fusion transcripts, anti-proliferation, inhibition of angiogenesis) may contribute to efficacy in APL.”
“The mean plasma elimination t1/2 value in patients receiving arsenic trioxide was 92 hours. This 92-hour plasma elimination half-life is consistent with the reported 3 to 5 day urinary excretion half-life for arsenic.”
Working under the parallel aged-care framework? Aged-care equivalent →
“In vitro enzymatic studies with human liver microsomes revealed that arsenic trioxide has no inhibitory activity on substrates of the major cytochrome P450 enzymes such as 1A2, 2A6, 2B6, 2C8, 2C9, 2C19, 2D6, 2E1, 3A4/5, and 4A9/11.”